Which graft is best for women? new trial tests vein vs artery in bypass surgery

NCT ID NCT06179329

Recruiting now Disease control Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for women under 75 who need heart bypass surgery for three blocked arteries. It compares two types of grafts for the second most important artery: a leg vein harvested with a special 'no-touch' technique versus a wrist artery. The goal is to see which graft stays open longer, helping doctors choose the best option for women.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this trial could show that the no-touch saphenous vein technique is a better option than the radial artery for the second graft in women, potentially improving long-term outcomes after bypass surgery.
What could go wrong: This is a relatively small trial (150 women) and only looks at graft patency at one year. Results may not apply to all women or to longer timeframes, and there are standard surgical risks like infection or heart attack.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC DISEASE GRAFT FAILURE SURGERY COMPLICATIONS

Contacts and locations

Locations

Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo
RECRUITING

São Paulo, São Paulo, 05403-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.